NovoCure Ltd (NVCR) Stock
2 members of Congress disclosed 3 trades in NVCR since 2019: 2 purchases and 1 sale, most recently Marie Newman (purchase, Jul 2, 2021). Company insiders reported 0 open-market buys and 1 sale on SEC Form 4 in the 90 days to Nov 10, 2026.
Which members of Congress traded NovoCure Ltd (NVCR)?
Most recent: Marie Newman (purchase, Jul 2, 2021); records start Jun 19, 2019.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Marie Newman D-IL · House | 2021-07-02 | purchase | $15k – $50k |
| Donna Shalala D-FL · House | 2019-06-24 | sale | $1k – $15k |
| Donna Shalala D-FL · House | 2019-06-19 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 9, 2026.
See all NVCR political trades →Are NovoCure Ltd insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Nov 2, 26 | Puri Michal Nath | Chief Human Resources Officer | SELL | 660 | $9K |
SEC Form 4 filings as of Nov 10, 2026
See cluster-buy signals across all tickers →NVCR price chart
Powered by TradingViewWhat does NovoCure Ltd do?
Novocure Ltd. is a global oncology company that develops and commercializes Tumor Treating Fields (TTFields), an innovative, non-invasive cancer therapy using alternating electric fields tuned to specific frequencies to disrupt cancer cell division while sparing healthy tissue. Its commercialized products, including Optune Gio, Optune Lua, and Optune Pax, are approved in certain countries for treating adult patients with glioblastoma, pancreatic cancer, non-small cell lung cancer, and malignant pleural mesothelioma. Novocure Ltd. focuses on extending survival in aggressive solid tumor cancers through this proprietary platform, which targets tumors without many traditional chemotherapy side effects. The company manufactures and distributes these wearable devices internationally, with operations spanning North America, Europe, the Middle East, Asia, Germany, and Japan. It conducts ongoing phase 2 and phase 3 clinical trials exploring TTFields in glioblastoma, non-small cell lung cancer, and pancreatic cancer, alongside a pipeline including products like Trident, Lunar-2, Panova-3, and Metis. Founded in 2000 and headquartered in St. Helier, Jersey, Novocure Ltd. plays a significant role in advancing novel oncology treatments.